Founded in 1971 by the late Jack Aviv, Aviv Biomedical initially serviced spectrophotometers, circular dichroism spectrometers and spectrofluorometers. A medical instrumentation developer, in 1975 -under license from Bell Telephone Research,- the company introduced a front surface fluorescence instrument to detect iron deficiency and lead poisoning in the blood, known as a Hematofluorometer. Specializing in circular dichroism (CD) spectroscopy, fluorescence detection for analytical ultracentrifugation, UV-Vis-IR spectroscopy, and fluorescence spectroscopy a number of innovative technologies were introduced to include CD spectroscopy - the first to have computer user interface, thermoelectric temperature control, simultaneous fluorescence measurements, fluorescence detected circular dichroism, super conducting magnetic CD, multiple automated titration experiments, and macro language. In 2018, the firm announced launch of a new initiative to identify one or more global partners for commercialisation of its newest product, the Bilirubin Hematofluorometer System (AVIV-BHS), for assessment of jaundice in newborn babies. For the first time, this new approach enables the the rapid measurement in neonates of Bilirubin Binding Capacity (BBC), a critical factor in preventing or allowing the development of neonatal jaundice. Bilirubin is neurotoxic, and high levels following birth can result in grave illnesses including seizures,cerebral palsy and kernicterus. Neonatal jaundice, caused by hyperbilirubinemia, is a common disorder in ~60% of newborns with ~18% of these at risk for neurological disorders or death. All modern hospitals monitor neonatal bilirubin levels (Total Serum Bilirubin or TSB), however, predicting risk solely on TSB levels is known to be inadequate.
